Search the Newsreel

Mangoceuticals Inc (MGRX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Mangoceuticals Inc (MGRX), noting its current valuation score of 9.10, which ranks 19th in the Healthcare Providers & Services industry. It states the company's P/E ratio is -0.42 but highlights that relevant data for P/B, P/S, and …

Mangoceuticals Inc (MGRX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Mangoceuticals Inc (MGRX), detailing its current risk score, beta value, and various volatility metrics. The company's risk score is 1.20, ranking 66 out of 75 in the Healthcare Providers & Services industry, with a beta of 0.00 …

Mangoceuticals Inc (MGRX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health analysis of Mangoceuticals Inc (MGRX), noting its current financial score of 5.70 and low operating efficiency. The company's latest quarterly revenue decreased by 37.91% year-over-year, and net profit declined by 29.68%. Key financial metrics for quality of earnings, …

Live webcast set for AngioDynamics' Aug. 11 presentation

AngioDynamics, Inc. announced its management team will participate in upcoming investor conferences, including the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026. A live webcast of the Canaccord …

Tango Therapeutics Inc (TNGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides an overview of Tango Therapeutics Inc (TNGX), including its current stock price and market capitalization. It attempts to present a revenue breakdown by business segment and region, but notes that this relevant data has not yet been disclosed by …

Why Mkango Resources (LSE:MKA) Is In Focus As Defensive UK Shares Regain Attention

Tango Therapeutics Inc (TNGX) Financial Health: Profitability & Balance Sheet Analysis

Tango Therapeutics Inc (TNGX) has a robust financial status with a score of 8.24, ranking 57th in the Biotechnology & Medical Research industry, despite a 100% year-over-year decrease in quarterly revenue and a 14.14% decrease in net profit. The analysis highlights high operating efficiency …

Mangoceuticals Inc (MGRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey reports on Mangoceuticals Inc (MGRX) revenue breakdown. However, it indicates that the company has not yet disclosed relevant data regarding its business segments, regional revenue, and profit contribution. The page displays current stock information and notes the absence of detailed …

Mangoceuticals Inc (MGRX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Mangoceuticals Inc's (MGRX) shareholder structure, including major individual and institutional holdings. It lists the proportion of shares held by entities like Armistice Capital LLC, Cohen (Jacob D.), and Ikarian Capital LLC, as well as by different shareholder …

AngioDynamics Inc (ANGO) Balance Sheet

This article provides key balance sheet information for AngioDynamics Inc (ANGO), including quarterly and annual data for various assets, liabilities, and shareholders' equity components. It allows users to evaluate the company's financial health, analyze fundamentals, and calculate key financial ratios. The data highlights recent …

Cango Inc. Launches 10-for-1 Share Consolidation as Post-Consolidation Trading Begins on NYSE

Cango Inc., a Bitcoin mining company, implemented a 10-for-1 share consolidation for its Class A and Class B ordinary shares, with post-consolidation trading beginning on the NYSE on July 21, 2026, under the ticker CANG. The company, which also operates an international used car …

AngioDynamics Inc (ANGO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for AngioDynamics Inc (ANGO) as of April 6. It shows that the majority of its revenue (85.79%, or $67.28M) comes from the United States, with 14.21% ($11.14M) from international regions. The article notes that relevant data for business …

AngioDynamics Inc

AngioDynamics Inc (ANGO) is a medical technology company focused on vascular health and cancer treatment. The company designs, manufactures, and sells devices for vascular access, peripheral vascular disease, oncology, and surgical settings. Its product categories include oncology, venous therapies, vascular interventions, and ports, utilized …

Mangoceuticals Inc (MGRX) Income Statement

This article presents the quarterly and annual income statements for Mangoceuticals Inc (MGRX), providing detailed financial figures from FY2022Q3 to FY2026Q1, including revenue, cost of revenue, operating expenses, and net income. It also includes key financial metrics like EPS and offers an FAQ section …

Mangoceuticals Inc MGRX Cash Flow Statement

This article provides a detailed quarterly and annual cash flow statement for Mangoceuticals Inc (MGRX), including sections on operating, investing, and financing cash flows. It breaks down various components like net income, non-cash items, and changes in working capital, offering insight into the company's …

MGRX|Mangoceuticals Inc|Price:0.521|Chg%:-0.037

This article provides a financial overview of Mangoceuticals Inc. (MGRX), including its current stock price, market cap, and key financial summaries. It details the company's income statement, balance sheet, and cash flow statement, offering quarterly and annual data for various financial indicators. The report …

Tango Therapeutics Inc (TNGX) Cash Flow

This article provides a detailed quarterly and annual cash flow statement for Tango Therapeutics Inc (TNGX), covering operating, investing, and financing activities. It also includes frequently asked questions explaining different types of cash flow and TNGX's recent performance in these areas, such as its …

Tango Therapeutics Inc (TNGX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Tango Therapeutics Inc (TNGX), identifying its major shareholders and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding over several quarters, and recent shareholder activities by top firms. The report also lists related ETFs that …

Mangoceuticals Inc (MGRX) Institutional Confidence

This article from TradingKey provides an overview of Mangoceuticals Inc (MGRX) with a focus on institutional confidence. It details key shareholder activities, including shares held and percentage changes by major institutional investors like Armistice Capital LLC, Cohen (Jacob D.), and Geode Capital Management. The …

AngioDynamics (NASDAQ: ANGO) CEO settles performance share grant

AngioDynamics (NASDAQ: ANGO) CEO James C. Clemmer settled a performance share grant from 2023, receiving 52,358 shares of Common Stock. The original grant of 184,361 units was based on multi-year performance metrics, with the remaining units forfeited. To cover tax withholding obligations, 26,728 shares …

AngioDynamics Inc (ANGO) CFO performance shares vest, tax withheld

AngioDynamics Inc. CFO Stephen A. Trowbridge received 16,296 shares of common stock from the vesting of performance share units, which were part of a target grant of 57,381 units on July 19, 2023. The shares vested based on performance metrics and relative total shareholder …

AngioDynamics (ANGO) SVP receives shares from PSU vesting, with tax withholding

Chad Thomas Campbell, SVP/GM Vascular Access at AngioDynamics (ANGO), received 6,466 shares of common stock from the vesting of performance share units, which were originally granted on July 19, 2023. To cover tax withholding obligations, 2,330 shares were disposed of at $13.82 per share. …

TradingKey

This article provides a detailed quarterly and annual income statement for Tango Therapeutics Inc (TNGX). It includes key financial metrics such as total revenue, operating expenses, research and development expenses, operating profit, net non-operating interest income/expenses, other non-operating income/expenses, income before and after tax, …

AngioDynamics (NASDAQ: ANGO) executive settles 20,052 performance units

Warren Nighan Jr., SVP Quality and Regulatory at AngioDynamics (NASDAQ: ANGO), had a 2023 performance share unit grant settle, resulting in 5,694 shares of common stock being issued from a target of 20,052 units. The remaining units were forfeited, and 1,671 shares were withheld …

AngioDynamics Inc. (ANGO) SVP receives 8,047 shares, 4,506 withheld for tax

AngioDynamics Inc.'s SVP International, Laura Piccinini, received 8,047 common shares from the vesting of performance share units granted in July 2023. Of these, 4,506 shares were withheld for tax obligations at $13.82 per share, and the remaining 20,289 units from the original grant were …

Discontinued operations of Cango Inc. Class A – MUN:9C00

This article reports on the discontinued operations of Cango Inc. Class A, traded under the ticker MUN:9C00 on the Munich Stock Exchange. The brief entry provides no specific financial details or reasons for the discontinuation, serving primarily as a status update for investors following …

How Much Upside is Left in Tango Therapeutics (TNGX)? Wall Street Analysts Think 49.48%

Wall Street analysts project a significant upside for Tango Therapeutics (TNGX), with a mean price target suggesting a 49.5% increase. Despite some variability in individual estimates, there's strong agreement among analysts regarding the company's potential for better-than-expected earnings, reinforced by a positive trend in …

Cango Inc. Revenue Breakdown – NYSE:CANG

Dilution adjustment of Cango Inc. Class A – MUN:9C00

The article mentions a "Dilution adjustment of Cango Inc. Class A – MUN:9C00" on the Munich Stock Exchange. It provides general information about Cango Inc. Class A, including its market status and various data providers for its financials. However, the article itself contains no …

Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History

This article provides comprehensive financial information for Tango Therapeutics, Inc. (TNGX), including its current stock price, historical data, recent news, and analyst ratings. It details the company's focus on precision oncology and its drug development pipeline. The report also includes performance metrics, earnings trends, …

Return on invested capital % of Cango Inc. Class A – MUN:9C00

This article provides financial information for Cango Inc. Class A (MUN:9C00), specifically focusing on its return on invested capital percentage. The content appears to be an excerpt from a financial data platform, likely TradingView, presenting a quantitative financial metric for the company listed on …

TNGX: Tango Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides an overview of Tango Therapeutics Inc (TNGX), including its latest stock price, market capitalization, key financial metrics, and upcoming earnings date. It also features recent news headlines related to TNGX and discussions on other trending stocks like SPY, HIMS, and NOW, …

Return on assets % of Cango Inc. Class A – MUN:9C00

The article focuses on the "Return on assets %" for Cango Inc. Class A, traded on the Munich Stock Exchange under the ticker 9C00. It presents a screen from TradingView for the specific financial metric, indicating that the market was closed with no trades …

CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46

CCORF has reiterated its Buy rating for Tango Therapeutics (TNGX.US), maintaining its target price at $46. This reflects a continued positive outlook on the company's stock performance by the firm.

Operating cash flow per share of Cango Inc. Class A – MUN:9C00

This page from TradingView displays financial information, specifically focusing on the operating cash flow per share for Cango Inc. Class A (MUN:9C00). It highlights that the market is closed and no trades have occurred. The content is primarily a listing of navigation and footer …

Tango Therapeutics Inc (TNGX) Institutional Confidence

Tango Therapeutics Inc (TNGX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 123.32%, a significant quarter-over-quarter increase of 24.30%. Steven Cohen is the largest institutional shareholder, holding 568.45K shares.